Endogenous bradykinin and the renin and pressor responses to furosemide in humans.
نویسندگان
چکیده
In humans, bradykinin contributes to the acute renin response after ACE inhibition. To further explore the role of endogenous bradykinin in human renin regulation, we determined the effect of HOE 140, a specific bradykinin B(2) receptor antagonist, on the renin response to 0.5 mg/kg i.v. furosemide in a randomized, single blind, crossover design study of 10 healthy, salt-replete volunteers. HOE 140 did not affect basal plasma renin activity, aldosterone, mean arterial pressure, or heart rate. Furosemide administration increased plasma renin activity from 1.0 +/- 0.2 to 4.5 +/- 1.2 ng of angiotensin I/ml/h and there was no effect of HOE 140 (from 1.1 +/- 0.2 to 3.9 +/- 0.8 ng of angiotensin I/ml/h). Similarly, there was no effect of HOE 140 on the diuretic response to furosemide. Mean arterial pressure increased in response to furosemide after HOE 140 (82 +/- 2 to 94 +/- 2 mm Hg), but not after vehicle (81 +/- 3 to 85 +/- 2 mm Hg), whereas heart rate was unchanged. In conclusion, activation of the B(2) receptor by endogenous bradykinin does not contribute to the renin response to acute furosemide treatment in humans. However, bradykinin may contribute to blood pressure regulation under conditions in which the renin-angiotensin system is stimulated.
منابع مشابه
Role of Bradykinin and Mas Receptor Blockade in Renal Vascular Responses to Angiotensin 1-7 in Adult Female Rats
Background and purpose: Chronic kidney disease is among the common diseases in the world. Studies show that women are more protected against renal diseases compared to men. On the other hand, vasodilatory axises of renin angiotensin system (angiotensin 1-7 (Ang 1-7)- Mas receptor (MasR)), kallikrein-kinin, and nitric oxide (NO) play key roles in kidney function and circulation in females. There...
متن کاملPressor response to saralasin (1-sar-8-ala-angiotensin II) bolus injection in hypertensive patients.
A 10 mg bolus of the angiotensin blocker saralasin was injected 113 times in 68 subjects with essential or renovascular hypertension. Ninety percent of injections caused a transient increase in blood pressure, which correlated with plasma renin activity (PRA) (r = -0.54); Mean increase at 2 minutes was 21/13.4 mm Hg (P less than 0.001) and was independent of pre-injection control blood pressure...
متن کاملResponsiveness to pressor agents in experimental renovascular and steroid hypertension. Effects of converting enzyme inhibitor and nephrectomy.
To assess changes in responsireness to pressor agents in experimental hypertension, we examined pressor dose-response curves to graded doses of angiotensin II (All) and norepinephrine (NE) in anesthetized normal rats and rats with eariy (< 6 weeks) or chronic (> 4 months) two-kidney one clip renovascular hypertension and deoxycorticosterone (DOC) salt hypertension. Occupancy of receptors by end...
متن کاملThe role of renal kallikrein and prostaglandin in the control of renin release.
Renal prostaglandins and kallikrein are considered to play an important role in the control of renin release. Recently, we have shown that aprotinin, a kallikrein inhibitor, inhibits the stimulation of plasma renin activity (PRA) by either furosemide or a low sodium diet. However, the mechanisms of action of kallikrein are unknown. Since kallikrein may stimulate bradykinin and prostaglandin pro...
متن کاملAntihypertensive effects of angiotensin-(1-7).
Accumulating evidence suggests that angiotensin-(1-7)(Ang-(1-7)) is an important component of the renin-angiotensin system and that the actions of the peptide may either contribute to or oppose those of Ang II. Ang-(1-7) can be converted directly from Ang I bypassing prerequisite formation of Ang II. Formation of Ang-(1-7) is under the control of at least three endopeptidases depending on the t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The Journal of pharmacology and experimental therapeutics
دوره 295 2 شماره
صفحات -
تاریخ انتشار 2000